Wild type p53-dependent transcriptional upregulation of cathepsin L expression is mediated by C/EBPα in human glioblastoma cells
- 1 September 2010
- journal article
- Published by Walter de Gruyter GmbH in Biological Chemistry
- Vol. 391 (9), 1031-40
- https://doi.org/10.1515/bc.2010.103
Abstract
Mutations in the tumor suppressor gene p53 are frequent in human glioblastomas. Similarly cathepsin L, a lysosomal cysteine protease, is overexpressed and secreted by most human tumors including glioblastomas. However, hitherto there is no information on whether or not the mutation(s) in the p53 gene affect(s) expression of this protease. Using human glioblastoma cell lines harboring wild type and mutant p53, we demonstrate here for the first time that only the wild type but not the mutant p53 upregulates cathepsin L expression. By transfection of promoter reporter constructs, site-directed mutagenesis and chip assays we have established that wild type p53 elevates the levels of cathepsin L in these cells. It does so directly by binding to the cathepsin L promoter and also indirectly by inducing the expression of C/EBPα, which is crucial for the transcription of this protease. In view of its role in tumorigenesis, angiogenesis and tumor cell invasion, increased expression of cathepsin L in glioblastoma cells harboring wild type p53 might confer invasive ability and growth advantage to these cells. Therefore, use of cathepsin L inhibitors could prove useful in the management of these tumors.Keywords
This publication has 50 references indexed in Scilit:
- Cathepsin L, target in cancer treatment?Life Sciences, 2010
- The role of p53 in DNA damage-mediated cytotoxicity overrides its ability to regulate nucleotide excision repair in human fibroblastsMutagenesis, 2007
- Wild-type p53 Inhibits Nuclear Factor-κB–Induced Matrix Metalloproteinase-9 Promoter Activation: Implications for Soft Tissue Sarcoma Growth and MetastasisMolecular Cancer Research, 2006
- Antiangiogenic activity of BAI1 in vivo: implications for gene therapy of human glioblastomasCancer Gene Therapy, 2005
- Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genesOncogene, 2004
- p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastomaOncogene, 2000
- Combined radiation and p53 gene therapy of malignant glioma cellsCancer Gene Therapy, 1999
- Susceptibility of the cartilage collagens types II, IX and XI to degradation by the cysteine proteinases, cathepsins B and LFEBS Letters, 1990
- A New Wave of Enzymes for Cleaving ProhormonesScience, 1987
- Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.Proceedings of the National Academy of Sciences of the United States of America, 1979